Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 4:18 PM ET

Health Care Technology

Company Overview of GNS Healthcare, Inc.

Company Overview

GNS Healthcare, Inc. provides analytics solutions for the healthcare industry. It offers Reverse Engineering and Forward Simulation Technology, a supercomputer-enabled framework that automates the extraction of causal network models directly from observational data and uses high-throughput simulations to generate new knowledge. The company also provides real-world outcomes solutions for data that comes from electronic health records, claims, clinical programs, and incentive and reward programs; product development solutions for biopharmaceutical, diagnostic, consumer product, and medical device companies; and publications, conference abstracts, and presentations. It serves pharmaceutical and...

One Charles Park

Cambridge, MA 02142-1254

United States

Founded in 2000





Key Executives for GNS Healthcare, Inc.

Co-Founder, Chairman of the Board, Chief Executive Officer and President
Co-Founder and Executive Vice President
Chief Financial Officer
Chief Operating Officer
Chief Mathematics Officer
Compensation as of Fiscal Year 2015.

GNS Healthcare, Inc. Key Developments

GNS Healthcare, Inc. Announces Board Appointments

GNS Healthcare announced the expansion of its Strategic Advisory Board (SAB). Joining the SAB are Susan Weaver, MD, former Chief Medical Officer of Blue Cross and Blue Shield of North Carolina; Robert J. Perez, the former Chief Executive Officer of Cubist Pharmaceuticals, Inc.; Steve Eisenberg, MD, former Vice President, Healthcare Informatics for UnitedHealth Group subsidiary OptumHealth; and Timothy Thompson, Chairman and CEO of Intervention Insights. Dr. Weaver will assume a special role on the SAB, leading a Medical Care Management Task Force composed of clinical experts, including Dr. Eisenberg and Dr. Jan Berger, Vice Chair of the GNS Board of Directors and former Senior Vice President and Chief Clinical Officer for CVS Caremark.

GNS Healthcare, Inc. Presents at Boston Biotech Conferences 2015, Nov-12-2015 10:00 AM

GNS Healthcare, Inc. Presents at Boston Biotech Conferences 2015, Nov-12-2015 10:00 AM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States. Speakers: Iya Khalil, Co-Founder and Executive Vice President.

GNS Healthcare Introduces MAX for Metabolic Syndrome

GNS Healthcare announced the expansion of its big data-driven population health management suite of solutions with the introduction of MAX for Metabolic Syndrome. More than one-third of the U.S. population has metabolic syndrome, a disorder that can lead to chronic heart disease, stroke and diabetes. These conditions combine to account for almost 20% of overall healthcare costs in the United States. MAX for Metabolic Syndrome is the latest in a suite of population health management solutions from GNS. These GNS solutions are transforming population health management with a value-based approach that leverages precision medicine and transcends the traditional one-size-fits-all, rules-based model. GNS solutions analyze large, heterogeneous datasets to identify individuals who will benefit from programs to prevent disease progression, avoid complications, and improve individual health outcomes. The GNS solutions then match individuals to their personal optimal intervention. In contrast, rules-based approaches to population health rely on thresholds derived from averages across a population and, as a result, miss opportunities to deliver highly personalized care. MAX for Metabolic Syndrome predicts which of the five risk factors associated with metabolic syndrome will develop next in at-risk individuals. The GNS solution also matches each individual with the most efficient effective intervention to prevent the condition from developing. MAX for Metabolic Syndrome is based upon the unique GNS Meaningful Actions Accelerator (MAX) architecture. The MAX architecture leverages the company’s MeasureBase data warehouse and patented REFS machine learning and simulation platform to inform analytics models and discover new knowledge from large amounts of real-world data. GNS analytics models predict risk of negative outcomes, including adverse events, sub-optimal outcomes, and progression; quantify the effect of behavior changes; stratify populations based on individuals’ likelihood to engage; measure the power of interventions to change behavior; and match individuals to the most cost-efficient effective intervention.

Similar Private Companies By Industry

Company Name Region
MemVu, Inc. United States
SecureTrack, Inc. United States
Apple Medical Services United States
The Copperwood Group, Inc. United States
KIG Healthcare Solutions, Inc. United States

Recent Private Companies Transactions

Private Placement
May 11, 2015
Private Placement
February 19, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GNS Healthcare, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at